Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats
Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 19(2024), 4 vom: 28. Feb., Seite 293-301 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Souza, Aline de [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 20.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2023-0263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367608065 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367608065 | ||
| 003 | DE-627 | ||
| 005 | 20240420232231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM367608065 | ||
| 035 | |a (NLM)38270378 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Souza, Aline de |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a chylomicrons | |
| 650 | 4 | |a cycloheximide | |
| 650 | 4 | |a hydroxymethylnitrofurazone | |
| 650 | 4 | |a lymphatic system | |
| 650 | 4 | |a nanostructured lipid carrier | |
| 650 | 7 | |a hydroxymethylnitrofurazone |2 NLM | |
| 650 | 7 | |a Dimethyl Sulfoxide |2 NLM | |
| 650 | 7 | |a YOW8V9698H |2 NLM | |
| 650 | 7 | |a Chylomicrons |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Nitrofurazone |2 NLM | |
| 650 | 7 | |a X8XI70B5Z6 |2 NLM | |
| 700 | 1 | |a Scarim, Cauê Benito |e verfasserin |4 aut | |
| 700 | 1 | |a Cotrim, Paulo Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Junior, Fernando Barbosa |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, Bruno Alves |e verfasserin |4 aut | |
| 700 | 1 | |a Calixto, Leandro Augusto |e verfasserin |4 aut | |
| 700 | 1 | |a Correia, Cristiano Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a de Barros Araújo, Gabriel Lima |e verfasserin |4 aut | |
| 700 | 1 | |a Löbenberg, Raimar |e verfasserin |4 aut | |
| 700 | 1 | |a Bou-Chacra, Nádia Araci |e verfasserin |4 aut | |
| 700 | 1 | |a Breithaupt-Faloppa, Ana Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 19(2024), 4 vom: 28. Feb., Seite 293-301 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:4 |g day:28 |g month:02 |g pages:293-301 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 4 |b 28 |c 02 |h 293-301 | ||